Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of cancer"
DOI: 10.1016/j.ejca.2022.01.022
Abstract: PURPOSE Panphila evaluated pyrotinib plus trastuzumab, docetaxel and carboplatin as neoadjuvant therapy for early breast cancer (BC), and investigated the predictive role of immune cell subpopulations. PATIENTS AND METHODS In this multicentre phase 2 study, patients… read more here.
Keywords: cancer; phase; neoadjuvant pyrotinib; plus trastuzumab ... See more keywords